{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T02:35:44Z","timestamp":1774319744343,"version":"3.50.1"},"reference-count":37,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayerisches Zentrum f\u00fcr Krebsforschung (BZKF)","award":["545058105"],"award-info":[{"award-number":["545058105"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)","doi-asserted-by":"publisher","award":["545058105"],"award-info":[{"award-number":["545058105"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Munich Clinician Scientist Program (MCSP) and the BZKF","award":["545058105"],"award-info":[{"award-number":["545058105"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Early treatment assessment in metastatic renal cell carcinoma (mRCC) remains challenging due to the limited accuracy of current imaging methods. Given prostate-specific membrane antigen (PSMA) overexpression in mRCC, PSMA PET is a promising approach. Despite numerous studies on PSMA imaging in mRCC, data on PSMA uptake changes during systemic therapy are scarce. We analyzed PSMA uptake on PET after treatment initiation in mRCC patients. Methods: A retrospective single-center analysis of mRCC patients who underwent [18F]PSMA-1007 PET\/CT before (PET1) and at a mean of 9.5 weeks after (PET2) starting systemic therapy was conducted. PSMA uptake in metastatic lesions was compared by region and RCC subtype. Uptake differences between PET1 and PET2 were analyzed using an unpaired t-test. Results: This study included 25 patients (mean age 65.2 \u00b1 14.7 years; 20 male) with mRCC. A total of 113 (PET1) and 48 (PET2) metastases were assessed. Lymph node metastases showed stable PSMA uptake (median SUVmax) after treatment (7.8 vs. 7.7, p = 0.77), while uptake by bone (6.4 vs. 12.4, p = 0.03) and lung metastases (4.5 vs. 8.1, p = 0.004) increased significantly. SUV stability in lymph nodes was independent of RCC subtype (ccRCC: p = 0.48, pRCC: p &gt; 0.99). Bone (6.6 vs. 15.9, p = 0.008) and lung metastases (4.8 vs. 8.1, p = 0.02) had higher PSMA uptake in ccRCC, unlike pRCC (bone: 6.2 vs. 6.0, p = 0.86). Conclusions: Alterations of PSMA-radioligand uptake are seen in bone and pulmonary metastases but not in lymph node metastases after initiation of systemic treatment in patients with mRCC. ccRCC has a higher PSMA uptake than other RCC subtypes.<\/jats:p>","DOI":"10.3390\/cancers17111736","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T10:24:45Z","timestamp":1747909485000},"page":"1736","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Changes of Prostate-Specific Membrane Antigen-Radioligand Uptake on PET with Systemic Therapy in Patients with Metastatic Renal Cell Carcinoma"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3175-952X","authenticated-orcid":false,"given":"Sophie Carina","family":"Kunte","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Partner Site Munich, 80539 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-8438","authenticated-orcid":false,"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany"},{"name":"Ahmanson Translational Theranostics Division, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany"},{"name":"Die RADIOLOGIE, 80331 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Zahner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Peter","family":"Schmid","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Sch\u00f6ll","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iulia","family":"Blajan","sequence":"additional","affiliation":[{"name":"Department of Urology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel T.","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Mehrens","sequence":"additional","affiliation":[{"name":"Department of Radiology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-1986","authenticated-orcid":false,"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[{"name":"Department of Urology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4659-2262","authenticated-orcid":false,"given":"Alexander J.","family":"Tamalunas","sequence":"additional","affiliation":[{"name":"Department of Urology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany"},{"name":"The Russell H Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3291-9460","authenticated-orcid":false,"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[{"name":"Department of Urology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-6522","authenticated-orcid":false,"given":"Michael","family":"Staehler","sequence":"additional","affiliation":[{"name":"Department of Urology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Partner Site Munich, 80539 Munich, Germany"},{"name":"Ahmanson Translational Theranostics Division, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of Renal Cell Carcinoma: 2022 Update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Liu, Y. (2016). The Place of FDG PET\/CT in Renal Cell Carcinoma: Value and Limitations. Front. Oncol., 6.","DOI":"10.3389\/fonc.2016.00201"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic Therapy for Metastatic Renal-Cell Carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14737140.2019.1573678","article-title":"Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma","volume":"19","author":"Reed","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12032-018-1147-y","article-title":"Check point inhibitors a new era in renal cell carcinoma treatment","volume":"35","author":"Alsharedi","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bui, V.N., Unterrainer, L.M., Brendel, M., Kunte, S.C., Holzgreve, A., Allmendinger, F., Bartenstein, P., Klauschen, F., Unterrainer, M., and Staehler, M. (2023). PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches. Biomedicines, 11.","DOI":"10.3390\/biomedicines11113095"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.humpath.2018.08.006","article-title":"High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma","volume":"83","author":"Polifka","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/1754-9485.12590","article-title":"Utility of 68Ga prostate specific membrane antigen\u2014Positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma","volume":"61","author":"Siva","year":"2017","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.euf.2018.08.004","article-title":"The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography for the Evaluation of Renal Cancer","volume":"6","author":"Evangelista","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13550-016-0231-6","article-title":"Pilot study: Use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour","volume":"6","author":"Rhee","year":"2016","journal-title":"EJNMMI Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/RLU.0000000000003002","article-title":"18F-PSMA 1007 in Suspected Renal Cell Carcinoma","volume":"45","author":"Marafi","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"111218","DOI":"10.1016\/j.ejrad.2023.111218","article-title":"Potential role of 68Ga-PSMA PET\/CT in metastatic renal cell cancer: A prospective study","volume":"170","author":"Aggarwal","year":"2024","journal-title":"Eur. J. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00259-020-05165-3","article-title":"18F-PSMA-1007 PET\/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: Preliminary results","volume":"48","author":"Mittlmeier","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","article-title":"Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy","volume":"45","author":"Seitz","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2967\/jnumed.116.181768","article-title":"Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging","volume":"58","author":"Cardinale","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5603\/NMR.2014.0022","article-title":"Effect of furosemide administration before F-18 fluorodeoxyglucose positron emission tomography\/computed tomography on urine radioactivity and detection of uterine cervical cancer","volume":"17","author":"Gorczewska","year":"2014","journal-title":"Nucl. Med. Rev. Cent. East. Eur."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00259-022-05970-y","article-title":"Flare on [18F]PSMA-1007 PET\/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: Possible marker of tumor aggressiveness in treatment-na\u00efve metastatic prostate cancer patients","volume":"50","author":"Malaspina","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/cts.12943","article-title":"Tyrosine Kinase Inhibitors Reduce Glucose Uptake by Binding to an Exofacial Site on hGLUT-1: Influence on 18F-FDG PET Uptake","volume":"14","author":"Damaraju","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11307-018-1271-2","article-title":"Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET\/CT","volume":"21","author":"Yin","year":"2019","journal-title":"Mol. Imaging Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s11307-022-01725-1","article-title":"68Ga-PSMA-11 PET\/CT Parameter Correlates with Pathological VEGFR-2\/PDGFR-\u03b2 Expression in Renal Cell Carcinoma Patients","volume":"24","author":"Gao","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gasparro, D., Scarlattei, M., Silini, E.M., Migliari, S., Baldari, G., Cervati, V., Graziani, T., Campanini, N., Maestroni, U., and Ruffini, L. (2023). High Prognostic Value of 68Ga-PSMA PET\/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry. Diagnostics, 13.","DOI":"10.3390\/diagnostics13193082"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.urolonc.2021.04.013","article-title":"Papillary renal cell carcinoma: Review","volume":"39","author":"Mendhiratta","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1590\/s1677-5538.ibju.2023.0312","article-title":"Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET\/CT and 18F-FDG PET\/CT in identifying adverse pathology of clear-cell renal cell carcinoma: A prospective study","volume":"49","author":"Chen","year":"2023","journal-title":"Int. Braz. J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12149-019-01371-8","article-title":"Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET\/CT","volume":"33","author":"Meyer","year":"2019","journal-title":"Ann. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2967\/jnumed.123.267175","article-title":"First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma","volume":"65","author":"Hofman","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"LBA602","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA602","article-title":"Results from phase 3 study of 89Zr-DFO-girentuximab for PET\/CT imaging of clear cell renal cell carcinoma (ZIRCON)","volume":"41","author":"Shuch","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2967\/jnumed.113.131110","article-title":"Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma","volume":"55","author":"Muselaers","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/j.crad.2023.01.003","article-title":"Exploration of 68Ga-labelled prostate-specific membrane antigen-11 PET\/CT parameters for identifying PBRM1 status in primary clear cell renal cell carcinoma","volume":"78","author":"Wang","year":"2023","journal-title":"Clin. Radiol."},{"key":"ref_33","first-page":"1","article-title":"Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives","volume":"1855","author":"Joosten","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/pr.114.010215","article-title":"The great escape; the hallmarks of resistance to antiangiogenic therapy","volume":"67","author":"Huijbers","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/RLU.0000000000004725","article-title":"Rapid Tumor Washout of 177 Lu-PSMA Radioligand in Renal Cell Carcinoma","volume":"48","author":"Zhang","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2967\/jnumed.118.215434","article-title":"Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer","volume":"64","author":"Seifert","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1007\/s00259-019-04636-6","article-title":"PSMA PET\/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma","volume":"47","author":"Mittlmeier","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/11\/1736\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:38:31Z","timestamp":1760031511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/11\/1736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["cancers17111736"],"URL":"https:\/\/doi.org\/10.3390\/cancers17111736","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}